Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?
Journal of Clinical Oncology · 2025-12 · 43 (34) · 3631-3635
DOI: 10.1200/jco-25-01932 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Clinical Oncology, 2025-12. Verfasst von Davide Rossi. Beteiligte Einrichtung: Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
- Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
ORCID-Profile: Davide Rossi
Zitieren
APA
Rossi, D. (2025). Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?. Journal of Clinical Oncology, 43(34), 3631-3635. https://doi.org/10.1200/jco-25-01932
Vancouver
Rossi D. Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?. Journal of Clinical Oncology. 2025;43(34):3631-3635. doi:10.1200/jco-25-01932
BibTeX
@article{Rossi2025,
author = {Rossi, Davide},
title = {Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {34},
pages = {3631--3635},
doi = {10.1200/jco-25-01932}
}
EUVIMED